Video
Author(s):
Cath O'Niell, chief scientific officer at SkinBioTherapeutics and professor of translational dermatology at the University of Manchester, discusses her recent research on developing probiotics to treat psoriasis and other inflammatory skin diseases.
With new and emerging biologic therapies for psoriasis seemingly popping up daily, one research team is seeking a new route for treatment with the development of a probiotic specifically tailored for the inflammatory skin disease.
Cath O'Niell, chief scientific officer at SkinBioTherapeutics and professor of translational dermatology at the University of Manchester, sits down with Dermatology Times to discuss her latest research and how probiotics might be a new viable therapy for other inflammatory skin disease besides psoriasis.